Logo image of ORKA

ORUKA THERAPEUTICS INC (ORKA) Stock Fundamental Analysis

USA - NASDAQ:ORKA - US6876041087 - Common Stock

27.13 USD
+0.48 (+1.8%)
Last: 10/23/2025, 4:10:10 PM
27.13 USD
0 (0%)
After Hours: 10/23/2025, 4:10:10 PM
Fundamental Rating

3

Overall ORKA gets a fundamental rating of 3 out of 10. We evaluated ORKA against 534 industry peers in the Biotechnology industry. ORKA has a great financial health rating, but its profitability evaluates not so good. ORKA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ORKA has reported negative net income.
ORKA had a negative operating cash flow in the past year.
ORKA had negative earnings in each of the past 5 years.
ORKA had a negative operating cash flow in each of the past 5 years.
ORKA Yearly Net Income VS EBIT VS OCF VS FCFORKA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With a decent Return On Assets value of -27.97%, ORKA is doing good in the industry, outperforming 69.66% of the companies in the same industry.
With a decent Return On Equity value of -29.09%, ORKA is doing good in the industry, outperforming 77.72% of the companies in the same industry.
Industry RankSector Rank
ROA -27.97%
ROE -29.09%
ROIC N/A
ROA(3y)-19.43%
ROA(5y)-22.56%
ROE(3y)-20.05%
ROE(5y)-23.79%
ROIC(3y)N/A
ROIC(5y)N/A
ORKA Yearly ROA, ROE, ROICORKA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ORKA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORKA Yearly Profit, Operating, Gross MarginsORKA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for ORKA has been increased compared to 1 year ago.
ORKA has more shares outstanding than it did 5 years ago.
ORKA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ORKA Yearly Shares OutstandingORKA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ORKA Yearly Total Debt VS Total AssetsORKA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 55.68 indicates that ORKA is not in any danger for bankruptcy at the moment.
ORKA's Altman-Z score of 55.68 is amongst the best of the industry. ORKA outperforms 97.19% of its industry peers.
ORKA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 55.68
ROIC/WACCN/A
WACCN/A
ORKA Yearly LT Debt VS Equity VS FCFORKA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 27.42 indicates that ORKA has no problem at all paying its short term obligations.
With an excellent Current ratio value of 27.42, ORKA belongs to the best of the industry, outperforming 97.57% of the companies in the same industry.
A Quick Ratio of 27.42 indicates that ORKA has no problem at all paying its short term obligations.
The Quick ratio of ORKA (27.42) is better than 97.57% of its industry peers.
Industry RankSector Rank
Current Ratio 27.42
Quick Ratio 27.42
ORKA Yearly Current Assets VS Current LiabilitesORKA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 31.66% over the past year.
EPS 1Y (TTM)31.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ORKA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.36% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y35.25%
EPS Next 2Y11%
EPS Next 3Y8.36%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ORKA Yearly EPS VS EstimatesORKA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2017 2018 2019 2024 2025 2026 2027 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ORKA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ORKA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ORKA Price Earnings VS Forward Price EarningsORKA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORKA Per share dataORKA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11%
EPS Next 3Y8.36%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ORKA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORUKA THERAPEUTICS INC

NASDAQ:ORKA (10/23/2025, 4:10:10 PM)

After market: 27.13 0 (0%)

27.13

+0.48 (+1.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-12 2025-11-12
Inst Owners91.67%
Inst Owner Change0.1%
Ins Owners3.8%
Ins Owner Change0%
Market Cap1.31B
Revenue(TTM)N/A
Net Income(TTM)-99977000
Analysts88.75
Price Target43.73 (61.19%)
Short Float %8.65%
Short Ratio11.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.23%
Min EPS beat(2)7.96%
Max EPS beat(2)22.5%
EPS beat(4)3
Avg EPS beat(4)-49.05%
Min EPS beat(4)-256.21%
Max EPS beat(4)29.55%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.57%
PT rev (3m)8.54%
EPS NQ rev (1m)5.32%
EPS NQ rev (3m)-6.67%
EPS NY rev (1m)-3.15%
EPS NY rev (3m)-1.45%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.82
P/tB 3.82
EV/EBITDA N/A
EPS(TTM)-2.81
EYN/A
EPS(NY)-2.67
Fwd EYN/A
FCF(TTM)-2.02
FCFYN/A
OCF(TTM)-2.02
OCFYN/A
SpS0
BVpS7.1
TBVpS7.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -27.97%
ROE -29.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-19.43%
ROA(5y)-22.56%
ROE(3y)-20.05%
ROE(5y)-23.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 27.42
Quick Ratio 27.42
Altman-Z 55.68
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)233.92%
Cap/Depr(5y)234.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.32%
EPS Next Y35.25%
EPS Next 2Y11%
EPS Next 3Y8.36%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-229.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1459.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1455.31%
OCF growth 3YN/A
OCF growth 5YN/A